Perioperative Cancer Cell Dissemination and Systemic Immune Suppression in Resectable Ductal Pancreatic Adenocarcinoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00495924|
Recruitment Status : Completed
First Posted : July 3, 2007
Last Update Posted : July 8, 2009
|Condition or disease||Intervention/treatment|
|Pancreatic Neoplasms Adenocarcinoma Neoplasm Circulating Cells Tumor Markers, Biological Monitoring, Immunologic||Procedure: Pancreatic resection (PD)|
Show Detailed Description
|Study Type :||Observational|
|Estimated Enrollment :||100 participants|
|Official Title:||Prognostic Relevance of Perioperative Cancer Cell Dissemination and Systemic Immune Suppression in Resectable Ductal Pancreatic Adenocarcinoma|
|Study Start Date :||October 2006|
|Actual Study Completion Date :||October 2008|
Patients undergoing pancreaticoduodenectomy for pancreatic or peri-ampullary tumours.
Procedure: Pancreatic resection (PD)
PD is a standard therapeutic surgical procedure. No additional interventions are performed.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00495924
|Department of Abdominal Surgery, Catholic University Leuven|
|Leuven, Vlaams-Brabant, Belgium, B-3060|
|Study Director:||Baki Topal, MD, PhD||Catholic University Leuven, Belgium|
|Principal Investigator:||Gregory Sergeant, MD||Catholic University Leuven|